OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION CONFIDENTIAL TREATMENT REQUESTED UNDER 17 C.F.R. SECTION 240.24b-2 AMENDMENT NO. 4 TO RESEARCH AND DEVELOPMENT AGREEMENTResearch and Development Agreement • January 2nd, 2014 • Intercept Pharmaceuticals Inc • Pharmaceutical preparations • New York
This Amendment No. 4 to Research and Development Agreement, dated November 5, 2013 (this “Amendment”), is entered into by and between INTERCEPT PHARMACEUTICALS, INC., a corporation organized and existing under the laws of Delaware, with its registered office at 18 Desbrosses Street, New York, NY 10013, USA (“INTERCEPT”) on the one hand and TES Pharma Srl, a corporation organized and existing under the laws of Italy, with its registered office at Via Settevalli 556, 06129, Perugia, Italy (“TES”) on the other hand.
OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION CONFIDENTIAL TREATMENT REQUESTED UNDER 17 C.F.R. SECTION 240.24b-2 AMENDMENT N°4 TO PRODUCT RESEARCH, DEVELOPMENT, LICENSE AND COMMERCIALIZATION AGREEMENTProduct Research, Development, License and Commercialization Agreement • January 2nd, 2014 • Intercept Pharmaceuticals Inc • Pharmaceutical preparations
a corporation organized and existing under the laws of Delaware, with registered office at 18 Desbrosses Street, New York, NY 10013, USA
OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION CONFIDENTIAL TREATMENT REQUESTED UNDER 17 C.F.R. SECTION 240.24b-2 AMENDMENT NO. 4 TO CONSULTING AND INTELLECTUAL PROPERTY (“IP”) AGREEMENTConsulting and Intellectual Property Agreement • January 2nd, 2014 • Intercept Pharmaceuticals Inc • Pharmaceutical preparations • New York
This Amendment No. 4 to Consulting and Intellectual Property (“IP”) Agreement (this “Amendment”), dated November 5, 2013, is entered into by and between INTERCEPT PHARMACEUTICALS, INC., a corporation organized and existing under the laws of Delaware, with its registered office at 18 Desbrosses Street, New York, NY 10013, USA (“INTERCEPT”), on the one hand and ROBERTO PELLICCIARI (“Consultant”), residing at Via U. Rocchi, 60, Perugia, Italy 06123, on the other hand:
